NASDAQ:PDLI - PDL BioPharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.33 +0.10 (+3.10 %) (As of 02/15/2019 04:00 PM ET)Previous Close$3.23Today's Range$3.22 - $3.3752-Week Range$2.25 - $3.37Volume1.08 million shsAverage Volume1.45 million shsMarket Capitalization$486.10 millionP/E Ratio5.29Dividend YieldN/ABeta0.5 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. The Pharmaceutical segment covers revenues from branded prescription medicine products being sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT for the rest of the world. The Medical Devices segment handles revenues from the LENSAR Laser System sales. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV. Receive PDLI News and Ratings via Email Sign-up to receive the latest news and ratings for PDLI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:PDLI Previous Symbol CUSIP69329Y10 Webwww.pdl.com Phone775-832-8500Debt Debt-to-Equity Ratio0.17 Current Ratio10.88 Quick Ratio10.61Price-To-Earnings Trailing P/E Ratio5.29 Forward P/E Ratio-6.53 P/E GrowthN/A Sales & Book Value Annual Sales$320.06 million Price / Sales1.52 Cash Flow$0.9174 per share Price / Cash Flow3.63 Book Value$5.48 per share Price / Book0.61Profitability EPS (Most Recent Fiscal Year)$0.63 Net Income$110.74 million Net Margins-28.41% Return on Equity7.72% Return on Assets5.67%Miscellaneous Employees87 Outstanding Shares145,976,000Market Cap$486.10 million OptionableOptionable PDL BioPharma (NASDAQ:PDLI) Frequently Asked Questions What is PDL BioPharma's stock symbol? PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI." How will PDL BioPharma's stock buyback program work? PDL BioPharma declared that its board has approved a share repurchase program on Monday, September 24th 2018, which allows the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 27.3% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board believes its shares are undervalued. How were PDL BioPharma's earnings last quarter? PDL BioPharma Inc (NASDAQ:PDLI) issued its quarterly earnings results on Wednesday, August, 8th. The biotechnology company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.04. The biotechnology company had revenue of $46.58 million for the quarter. PDL BioPharma had a negative net margin of 28.41% and a positive return on equity of 7.72%. View PDL BioPharma's Earnings History. When is PDL BioPharma's next earnings date? PDL BioPharma is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for PDL BioPharma. What price target have analysts set for PDLI? 1 analysts have issued twelve-month price objectives for PDL BioPharma's shares. Their predictions range from $3.00 to $3.00. On average, they anticipate PDL BioPharma's stock price to reach $3.00 in the next year. This suggests that the stock has a possible downside of 9.9%. View Analyst Price Targets for PDL BioPharma. What is the consensus analysts' recommendation for PDL BioPharma? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PDL BioPharma. Has PDL BioPharma been receiving favorable news coverage? News coverage about PDLI stock has been trending somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PDL BioPharma earned a coverage optimism score of 1.3 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. Who are some of PDL BioPharma's key competitors? Some companies that are related to PDL BioPharma include Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Momenta Pharmaceuticals (MNTA), Alector (ALEC), Iovance Biotherapeutics (IOVA), Orchard Therapeutics (ORTX), Autolus Therapeutics (AUTL), Rubius Therapeutics (RUBY), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Coherus Biosciences (CHRS), Editas Medicine (EDIT) and Fate Therapeutics (FATE). Who are PDL BioPharma's key executives? PDL BioPharma's management team includes the folowing people: Dominique Monnet, President, Chief Executive Officer & DirectorPeter S. Garcia, Chief Financial Officer & Vice PresidentChristopher Lewis Stone, Secretary, Vice President & General CounselJill M. Jene, Vice President-Business DevelopmentEdward Imbrogno, Vice President-Finance Who are PDL BioPharma's major shareholders? PDL BioPharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.62%), Dimensional Fund Advisors LP (8.53%), Connor Clark & Lunn Investment Management Ltd. (4.04%), Northern Trust Corp (3.22%), Brandes Investment Partners LP (3.06%) and D. E. Shaw & Co. Inc. (1.62%). View Institutional Ownership Trends for PDL BioPharma. Which institutional investors are selling PDL BioPharma stock? PDLI stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Bank of New York Mellon Corp, Acadian Asset Management LLC, Barclays PLC, KBC Group NV, Dimensional Fund Advisors LP, Paloma Partners Management Co and GSA Capital Partners LLP. View Insider Buying and Selling for PDL BioPharma. Which institutional investors are buying PDL BioPharma stock? PDLI stock was purchased by a variety of institutional investors in the last quarter, including Brandes Investment Partners LP, Prudential Financial Inc., RBF Capital LLC, Citigroup Inc., D. E. Shaw & Co. Inc., Two Sigma Investments LP, Weber Alan W and Ancora Advisors LLC. View Insider Buying and Selling for PDL BioPharma. How do I buy shares of PDL BioPharma? Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is PDL BioPharma's stock price today? One share of PDLI stock can currently be purchased for approximately $3.33. How big of a company is PDL BioPharma? PDL BioPharma has a market capitalization of $486.10 million and generates $320.06 million in revenue each year. The biotechnology company earns $110.74 million in net income (profit) each year or $0.63 on an earnings per share basis. PDL BioPharma employs 87 workers across the globe. What is PDL BioPharma's official website? The official website for PDL BioPharma is http://www.pdl.com. How can I contact PDL BioPharma? PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected] MarketBeat Community Rating for PDL BioPharma (NASDAQ PDLI)Community Ranking: 1.3 out of 5 ()Outperform Votes: 141 (Vote Outperform)Underperform Votes: 391 (Vote Underperform)Total Votes: 532MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe PDLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDLI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/15/2019 by MarketBeat.com StaffFeatured Article: How Do Front-End Loads Impact an Investment?